| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.851 | 0.001 | 0.851 | Prostacyclin antagonist | 0.738 0.002 DBMET00468 | ||
| 0.725 | 0.002 | 0.725 | Alpha 2 adrenoreceptor agonist | 0.583 0.002 DBMET00468 | ||
| 0.714 | 0.003 | 0.714 | Alpha adrenoreceptor agonist | 0.65 0.003 DBMET00468 | ||
| 0.676 | 0.004 | 0.676 | Antiadrenergic | 0.534 0.005 DBMET00468 | ||
| 0.672 | 0.004 | 0.672 | Adrenaline antagonist | 0.531 0.005 DBMET00468 | ||
| 0.602 | 0.003 | 0.602 | Alpha 2b adrenoreceptor antagonist | 0.505 0.004 DBMET00468 | ||
| 0.593 | 0.017 | 0.593 | Angiogenesis inhibitor | 0.526 0.025 DBMET00468 | ||
| 0.572 | 0.001 | 0.572 | Imidazoline I1 receptor antagonist | 0.139 0.002 DBMET00468 | ||
| 0.569 | 0.001 | 0.569 | Alpha 2a adrenoreceptor agonist | 0.474 0.001 DBMET00468 | ||
| 0.565 | 0.004 | 0.565 | Lck kinase inhibitor | 0.438 0.006 DBMET00468 | ||
| 0.544 | 0.003 | 0.544 | Vitronectin receptor antagonist | 0.352 0.003 DBMET00468 | ||
| 0.541 | 0.001 | 0.541 | Alpha 2b adrenoreceptor agonist | 0.252 0.002 DBMET00468 | ||
| 0.538 | 0.004 | 0.538 | Alpha 2a adrenoreceptor antagonist | 0.451 0.004 DBMET00468 | ||
| 0.53 | 0.041 | 0.53 | Analgesic | 0.489 0.052 DBMET00468 | ||
| 0.494 | 0.006 | 0.494 | Src kinase inhibitor | 0.369 0.016 DBMET00468 | ||
| 0.477 | 0.004 | 0.477 | Alpha 2 adrenoreceptor antagonist | 0.372 0.005 DBMET00468 | ||
| 0.482 | 0.009 | 0.482 | Anesthetic general | 0.465 0.01 DBMET00468 | ||
| 0.46 | 0.004 | 0.46 | Alpha 2c adrenoreceptor antagonist | 0.389 0.004 DBMET00468 | ||
| 0.477 | 0.045 | 0.477 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.365 0.135 DBMET00468 | ||
| 0.434 | 0.009 | 0.434 | Bone formation stimulant | 0.427 0.009 DBMET00468 | ||
| 0.46 | 0.038 | 0.46 | GABA C receptor rho-3 antagonist | 0.444 0.044 DBMET00468 | ||
| 0.403 | 0.001 | 0.403 | Alpha 2c adrenoreceptor agonist | 0.128 0.002 DBMET00468 | ||
| 0.353 | 0.017 | 0.353 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.295 0.028 DBMET00468 | ||
| 0.337 | 0.004 | 0.337 | Alpha 1 adrenoreceptor agonist | 0.247 0.005 DBMET00468 | ||
| 0.329 | 0.013 | 0.329 | Alpha adrenoreceptor antagonist | 0.227 0.023 DBMET00468 | ||
| 0.353 | 0.048 | 0.353 | Calcium channel activator | 0.308 0.084 DBMET00468 | ||
| 0.304 | 0.005 | 0.304 | 5 Hydroxytryptamine 7 antagonist | 0.191 0.013 DBMET00468 | ||
| 0.257 | 0.004 | 0.257 | Integrin beta5 antagonist | 0.087 0.004 DBMET00468 | ||
| 0.375 | 0.127 | 0.409 | Caspase 9 stimulant | 0.409 0.106 DBMET00468 | DBMET00468 | |
| 0.249 | 0.002 | 0.249 | Alpha 1b adrenoreceptor agonist | 0.199 0.003 DBMET00468 | ||
| 0.251 | 0.005 | 0.315 | Adrenaline agonist | 0.315 0.004 DBMET00468 | DBMET00468 | |
| 0.355 | 0.111 | 0.355 | 5 Hydroxytryptamine release inhibitor | 0.34 0.124 DBMET00468 | ||
| 0.265 | 0.026 | 0.265 | Protein-tyrosine kinase Lyn inhibitor | 0.179 0.053 DBMET00468 | ||
| 0.235 | 0.002 | 0.235 | Alpha 2d adrenoreceptor agonist | 0.142 0.002 DBMET00468 | ||
| 0.231 | 0.002 | 0.231 | Alpha 1a adrenoreceptor agonist | 0.174 0.003 DBMET00468 | ||
| 0.253 | 0.024 | 0.399 | Phospholipase C inhibitor | 0.399 0.01 DBMET00468 | DBMET00468 | |
| 0.217 | 0.003 | 0.217 | Integrin alphaVbeta3 antagonist | 0.152 0.004 DBMET00468 | ||
| 0.262 | 0.051 | 0.262 | Tyrosine kinase inhibitor | 0.146 0.092 DBMET00468 | ||
| 0.223 | 0.012 | 0.223 | Alpha 1b adrenoreceptor antagonist | 0.162 0.02 DBMET00468 | ||
| 0.215 | 0.008 | 0.215 | Platelet growth factor antagonist | 0.149 0.019 DBMET00468 | ||
| 0.201 | 0.001 | 0.201 | Alpha 1L adrenoreceptor agonist | 0.159 0.001 DBMET00468 | ||
| 0.203 | 0.014 | 0.203 | 5 Hydroxytryptamine 3A agonist | 0.168 0.026 DBMET00468 | ||
| 0.208 | 0.02 | 0.208 | Alpha 1 adrenoreceptor antagonist | 0.127 0.035 DBMET00468 | ||
| 0.2 | 0.013 | 0.2 | Interleukin 8 antagonist | 0.187 0.016 DBMET00468 | ||
| 0.187 | 0.003 | 0.187 | Integrin alphaVbeta1 antagonist | 0.148 0.003 DBMET00468 | ||
| 0.191 | 0.008 | 0.191 | Integrin antagonist | 0.118 0.014 DBMET00468 | ||
| 0.18 | 0.007 | 0.198 | NMDA 2B receptor antagonist | 0.198 0.006 DBMET00468 | DBMET00468 | |
| 0.172 | 0.001 | 0.172 | Integrin beta6 antagonist | 0.15 0.001 DBMET00468 | ||
| 0.25 | 0.081 | 0.25 | 5 Hydroxytryptamine uptake stimulant | 0.212 0.129 DBMET00468 | ||
| 0.169 | 0.012 | 0.169 | Alpha 1d adrenoreceptor antagonist | 0.105 0.022 DBMET00468 | ||
| 0.165 | 0.013 | 0.165 | Interleukin 2 antagonist | 0.123 0.04 DBMET00468 | ||
| 0.161 | 0.014 | 0.203 | NMDA 2 receptor antagonist | 0.203 0.009 DBMET00468 | DBMET00468 | |
| 0.176 | 0.029 | 0.176 | Aurora-C kinase inhibitor | 0.151 0.049 DBMET00468 | ||
| 0.214 | 0.068 | 0.228 | Nitric-oxide synthase stimulant | 0.228 0.051 DBMET00468 | DBMET00468 | |
| 0.223 | 0.079 | 0.223 | MAP-kinase-activated kinase 5 inhibitor | 0.204 0.099 DBMET00468 | ||
| 0.164 | 0.021 | 0.164 | Alpha 1a adrenoreceptor antagonist | 0.092 0.039 DBMET00468 | ||
| 0.181 | 0.041 | 0.181 | c-Src kinase inhibitor | 0.151 0.055 DBMET00468 | ||
| 0.226 | 0.087 | 0.279 | DNA synthesis inhibitor | 0.279 0.051 DBMET00468 | DBMET00468 | |
| 0.168 | 0.034 | 0.168 | Cyclooxygenase 3 inhibitor | 0.159 0.041 DBMET00468 | ||
| 0.129 | 0.004 | 0.129 | Integrin beta3 antagonist | 0.05 0.006 DBMET00468 | ||
| 0.136 | 0.015 | 0.136 | Prostaglandin-E synthase inhibitor | 0.111 0.022 DBMET00468 | ||
| 0.193 | 0.075 | 0.193 | 5 Hydroxytryptamine 3E antagonist | |||
| 0.147 | 0.039 | 0.147 | Ferrochelatase inhibitor | 0.098 0.073 DBMET00468 | ||
| 0.155 | 0.048 | 0.155 | 5 Hydroxytryptamine antagonist | |||
| 0.214 | 0.109 | 0.225 | Spasmolytic | 0.225 0.103 DBMET00468 | DBMET00468 | |
| 0.163 | 0.058 | 0.163 | GABA C receptor rho-2 antagonist | 0.146 0.079 DBMET00468 | ||
| 0.129 | 0.025 | 0.129 | ALK inhibitor | 0.087 0.051 DBMET00468 | ||
| 0.212 | 0.112 | 0.212 | 5 Hydroxytryptamine release stimulant | 0.184 0.137 DBMET00468 | ||
| 0.133 | 0.034 | 0.133 | Protein kinase C mu inhibitor | 0.108 0.05 DBMET00468 | ||
| 0.121 | 0.023 | 0.121 | Alpha 2d adrenoreceptor antagonist | 0.102 0.045 DBMET00468 | ||
| 0.117 | 0.019 | 0.117 | Nicotinic alpha4beta2 receptor antagonist | 0.091 0.039 DBMET00468 | ||
| 0.124 | 0.027 | 0.124 | Histamine N-methyltransferase inhibitor | 0.1 0.046 DBMET00468 | ||
| 0.108 | 0.013 | 0.108 | 5 Hydroxytryptamine 3A antagonist | |||
| 0.108 | 0.015 | 0.108 | 5 Hydroxytryptamine 3 antagonist | |||
| 0.21 | 0.118 | 0.257 | Tyrosine 3 hydroxylase inhibitor | 0.257 0.061 DBMET00468 | DBMET00468 | |
| 0.101 | 0.009 | 0.101 | Potassium channel (Ca-activated) blocker | |||
| 0.098 | 0.007 | 0.098 | Corticotropin releasing factor 2 receptor antagonist | 0.072 0.025 DBMET00468 | ||
| 0.131 | 0.043 | 0.144 | GABA C receptor agonist | 0.144 0.036 DBMET00468 | DBMET00468 | |
| 0.169 | 0.081 | 0.169 | Succinate dehydrogenase inhibitor | 0.168 0.083 DBMET00468 | ||
| 0.092 | 0.005 | 0.092 | Potassium channel small-conductance Ca-activated activator | |||
| 0.158 | 0.072 | 0.158 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.113 0.108 DBMET00468 | ||
| 0.18 | 0.096 | 0.18 | MAP kinase kinase 2 inhibitor | 0.147 0.124 DBMET00468 | ||
| 0.155 | 0.072 | 0.155 | Cytidine deaminase inhibitor | |||
| 0.119 | 0.037 | 0.119 | Electrolyte absorption antagonist | 0.103 0.053 DBMET00468 | ||
| 0.097 | 0.017 | 0.097 | 5 Hydroxytryptamine 5A antagonist | 0.07 0.031 DBMET00468 | ||
| 0.136 | 0.055 | 0.136 | Protein kinase (CK1) gamma 2 inhibitor | 0.099 0.085 DBMET00468 | ||
| 0.142 | 0.066 | 0.142 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.137 0.069 DBMET00468 | ||
| 0.172 | 0.097 | 0.172 | Focal adhesion kinase 2 inhibitor | |||
| 0.145 | 0.07 | 0.145 | Protein kinase (CK1) gamma inhibitor | |||
| 0.091 | 0.016 | 0.11 | NMDA 2A receptor antagonist | 0.11 0.011 DBMET00468 | DBMET00468 | |
| 0.099 | 0.025 | 0.099 | CXC chemokine receptor antagonist | 0.073 0.045 DBMET00468 | ||
| 0.091 | 0.017 | 0.091 | 5 Hydroxytryptamine 5 antagonist | 0.062 0.034 DBMET00468 | ||
| 0.154 | 0.08 | 0.154 | Polo-like kinase-3 inhibitor | |||
| 0.148 | 0.076 | 0.148 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.14 0.083 DBMET00468 | ||
| 0.149 | 0.078 | 0.164 | CF transmembrane conductance regulator agonist | 0.164 0.055 DBMET00468 | DBMET00468 | |
| 0.074 | 0.002 | 0.074 | Imidazoline I2 receptor antagonist | 0.019 0.004 DBMET00468 | ||
| 0.119 | 0.049 | 0.126 | Protein kinase (CK2) inhibitor | 0.126 0.044 DBMET00468 | DBMET00468 | |
| 0.09 | 0.02 | 0.09 | Potassium channel (ATP-sensitive) blocker | 0.081 0.027 DBMET00468 | ||
| 0.075 | 0.006 | 0.085 | Dopamine beta hydroxylase inhibitor | 0.085 0.005 DBMET00468 | DBMET00468 | |
| 0.157 | 0.09 | 0.157 | 3C-like protease (Human coronavirus) inhibitor | 0.142 0.116 DBMET00468 | ||
| 0.12 | 0.055 | 0.12 | CDK3/cyclin E inhibitor | |||
| 0.072 | 0.008 | 0.072 | Integrin alpha5beta1 antagonist | 0.056 0.014 DBMET00468 | ||
| 0.115 | 0.051 | 0.115 | CDC-like kinase 3 inhibitor | 0.105 0.069 DBMET00468 | ||
| 0.087 | 0.026 | 0.087 | ZAP-70 protein tyrosine kinase inhibitor | 0.076 0.04 DBMET00468 | ||
| 0.088 | 0.027 | 0.088 | 5 Hydroxytryptamine 1D antagonist | |||
| 0.061 | 0.002 | 0.061 | Complement factor 1r inhibitor | 0.049 0.003 DBMET00468 | ||
| 0.078 | 0.019 | 0.078 | Cyclin D1 inhibitor | 0.066 0.034 DBMET00468 | ||
| 0.131 | 0.075 | 0.131 | Cyclin-dependent kinase 7 inhibitor | |||
| 0.089 | 0.033 | 0.089 | Cyclin B3 inhibitor | 0.079 0.039 DBMET00468 | ||
| 0.139 | 0.086 | 0.139 | MAP kinase 3 inhibitor | |||
| 0.063 | 0.01 | 0.063 | Alpha 1d adrenoreceptor agonist | 0.044 0.021 DBMET00468 | ||
| 0.085 | 0.033 | 0.091 | GABA B receptor agonist | 0.091 0.024 DBMET00468 | DBMET00468 | |
| 0.061 | 0.009 | 0.061 | Diamine oxidase inhibitor | 0.039 0.024 DBMET00468 | ||
| 0.164 | 0.113 | 0.164 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.147 0.138 DBMET00468 | ||
| 0.151 | 0.1 | 0.16 | ATPase inhibitor | 0.16 0.085 DBMET00468 | DBMET00468 | |
| 0.171 | 0.121 | 0.171 | Cyclic AMP phosphodiesterase inhibitor | 0.158 0.14 DBMET00468 | ||
| 0.115 | 0.065 | 0.12 | Protein kinase (CK2) alpha inhibitor | 0.12 0.062 DBMET00468 | DBMET00468 | |
| 0.174 | 0.125 | 0.174 | ErbB-1 antagonist | 0.168 0.137 DBMET00468 | ||
| 0.103 | 0.053 | 0.117 | DNA directed RNA polymerase inhibitor | 0.117 0.039 DBMET00468 | DBMET00468 | |
| 0.064 | 0.015 | 0.064 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.144 | 0.096 | 0.147 | Arachidonic acid antagonist | 0.147 0.092 DBMET00468 | DBMET00468 | |
| 0.184 | 0.135 | 0.184 | Cardiotonic | 0.163 0.16 DBMET00468 | ||
| 0.064 | 0.016 | 0.064 | Potassium channel (Inward rectifier) activator | |||
| 0.158 | 0.111 | 0.158 | I kappa B kinase epsilon inhibitor | 0.143 0.127 DBMET00468 | ||
| 0.077 | 0.029 | 0.077 | 5 Hydroxytryptamine 3 agonist | |||
| 0.09 | 0.043 | 0.09 | Glycine receptor antagonist | |||
| 0.053 | 0.006 | 0.061 | Protein kinase (CK2) beta inhibitor | 0.061 0.005 DBMET00468 | DBMET00468 | |
| 0.061 | 0.015 | 0.061 | Potassium channel (ATP-sensitive) activator | |||
| 0.189 | 0.144 | 0.189 | 5 Hydroxytryptamine 1E antagonist | |||
| 0.169 | 0.124 | 0.254 | Aldehyde oxidase inhibitor | 0.254 0.081 DBMET00468 | DBMET00468 | |
| 0.095 | 0.05 | 0.124 | NMDA receptor antagonist | 0.124 0.034 DBMET00468 | DBMET00468 | |
| 0.134 | 0.09 | 0.134 | Pregnane X receptor agonist | |||
| 0.102 | 0.058 | 0.102 | MAP kinase 8 inhibitor | |||
| 0.085 | 0.044 | 0.085 | Focal adhesion kinase 1 inhibitor | |||
| 0.09 | 0.049 | 0.096 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.096 0.042 DBMET00468 | DBMET00468 | |
| 0.181 | 0.141 | 0.206 | Superoxide dismutase inhibitor | 0.206 0.111 DBMET00468 | DBMET00468 | |
| 0.051 | 0.012 | 0.051 | Potassium channel Kv1.1 blocker | |||
| 0.075 | 0.037 | 0.075 | 5 Hydroxytryptamine 1B antagonist | |||
| 0.092 | 0.054 | 0.096 | NADH dehydrogenase inhibitor | 0.096 0.048 DBMET00468 | DBMET00468 | |
| 0.112 | 0.076 | 0.122 | Transcription factor STAT6 inhibitor | 0.122 0.057 DBMET00468 | DBMET00468 | |
| 0.105 | 0.07 | 0.106 | GABA C receptor antagonist | 0.106 0.069 DBMET00468 | DBMET00468 | |
| 0.051 | 0.018 | 0.051 | Thymidine kinase inhibitor | 0.044 0.024 DBMET00468 | ||
| 0.04 | 0.007 | 0.04 | Thymidine phosphorylase inhibitor | 0.033 0.009 DBMET00468 | ||
| 0.084 | 0.051 | 0.084 | T cell inhibitor | |||
| 0.099 | 0.067 | 0.099 | Gastric antisecretory | |||
| 0.047 | 0.015 | 0.047 | 5 Hydroxytryptamine 2B agonist | |||
| 0.039 | 0.008 | 0.039 | Corticotropin releasing factor 1 receptor antagonist | 0.027 0.012 DBMET00468 | ||
| 0.103 | 0.072 | 0.105 | Protein kinase C gamma inhibitor | 0.105 0.069 DBMET00468 | DBMET00468 | |
| 0.117 | 0.087 | 0.117 | Nav1.2 sodium channel blocker | |||
| 0.097 | 0.067 | 0.097 | GABA C receptor rho-1 antagonist | |||
| 0.079 | 0.052 | 0.079 | MAP kinase 10 inhibitor | |||
| 0.035 | 0.01 | 0.046 | CXC chemokine 2 receptor antagonist | 0.046 0.006 DBMET00468 | DBMET00468 | |
| 0.062 | 0.037 | 0.062 | CDK9/cyclin T1 inhibitor | 0.051 0.05 DBMET00468 | ||
| 0.029 | 0.005 | 0.029 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.022 0.01 DBMET00468 | ||
| 0.029 | 0.005 | 0.029 | Sodium/hydrogen exchanger inhibitor | 0.018 0.012 DBMET00468 | ||
| 0.062 | 0.037 | 0.062 | Cyclin H inhibitor | |||
| 0.085 | 0.061 | 0.085 | Insulin growth factor antagonist | |||
| 0.033 | 0.009 | 0.033 | DNA polymerase III inhibitor | 0.027 0.022 DBMET00468 | ||
| 0.144 | 0.122 | 0.151 | Death-associated protein kinase 2 inhibitor | 0.151 0.104 DBMET00468 | DBMET00468 | |
| 0.083 | 0.061 | 0.091 | D-Ala-D-Ala ligase inhibitor | 0.091 0.042 DBMET00468 | DBMET00468 | |
| 0.031 | 0.009 | 0.031 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.026 0.02 DBMET00468 | ||
| 0.05 | 0.028 | 0.05 | CC chemokine 4 receptor antagonist | |||
| 0.035 | 0.013 | 0.035 | Elastase 3B inhibitor | |||
| 0.035 | 0.013 | 0.035 | Elastase 2B inhibitor | |||
| 0.035 | 0.013 | 0.035 | Elastase 3A inhibitor | |||
| 0.081 | 0.06 | 0.081 | Insulin like growth factor 1 antagonist | |||
| 0.143 | 0.123 | 0.143 | Psychostimulant | |||
| 0.071 | 0.052 | 0.071 | Phospholipase D inhibitor | |||
| 0.088 | 0.07 | 0.088 | CDK2/cyclin A inhibitor | |||
| 0.118 | 0.102 | 0.287 | Peroxidase inhibitor | 0.287 0.04 DBMET00468 | DBMET00468 | |
| 0.065 | 0.049 | 0.065 | Neuronal nicotinic receptor antagonist | 0.059 0.055 DBMET00468 | ||
| 0.089 | 0.074 | 0.131 | Creatine kinase inhibitor | 0.131 0.034 DBMET00468 | DBMET00468 | |
| 0.021 | 0.007 | 0.021 | Complement factor 1 inhibitor | 0.017 0.015 DBMET00468 | ||
| 0.065 | 0.053 | 0.065 | MDM2 inhibitor | |||
| 0.054 | 0.042 | 0.054 | 5 Hydroxytryptamine 6 antagonist | |||
| 0.063 | 0.052 | 0.063 | CDC7 inhibitor | |||
| 0.13 | 0.119 | 0.13 | Ca2+-transporting ATPase inhibitor | 0.129 0.128 DBMET00468 | ||
| 0.043 | 0.032 | 0.043 | Histamine H1 receptor agonist | |||
| 0.051 | 0.041 | 0.051 | Nicotinic receptor alpha7 subunit antagonist | |||
| 0.057 | 0.047 | 0.057 | Cyclin B1 inhibitor | 0.054 0.052 DBMET00468 | ||
| 0.107 | 0.097 | 0.107 | Glycogen synthase kinase-3 alpha inhibitor | |||
| 0.044 | 0.034 | 0.044 | Parathyroid hormone antagonist | |||
| 0.105 | 0.095 | 0.105 | Alpha-N-acetylglucosaminidase inhibitor | 0.105 0.095 DBMET00468 | ||
| 0.086 | 0.077 | 0.098 | MAP kinase kinase 1 inhibitor | 0.098 0.06 DBMET00468 | DBMET00468 | |
| 0.047 | 0.038 | 0.047 | Nicotinic receptor alpha4 subunit antagonist | |||
| 0.086 | 0.077 | 0.086 | Ephrin antagonist | |||
| 0.015 | 0.006 | 0.015 | DNA polymerase III polC-type inhibitor | |||
| 0.016 | 0.008 | 0.019 | Integrin alphaVbeta6 antagonist | 0.019 0.006 DBMET00468 | DBMET00468 | |
| 0.087 | 0.079 | 0.087 | Cyclin-dependent kinase 9 inhibitor | |||
| 0.12 | 0.113 | 0.122 | Death-associated protein kinase 1 inhibitor | 0.122 0.105 DBMET00468 | DBMET00468 | |
| 0.084 | 0.077 | 0.084 | Glutamate release inhibitor | |||
| 0.064 | 0.058 | 0.064 | Exportin-1 inhibitor | |||
| 0.032 | 0.026 | 0.032 | CDK6/cyclin D3 inhibitor | |||
| 0.166 | 0.16 | 0.171 | RNA-directed DNA polymerase inhibitor | 0.171 0.151 DBMET00468 | DBMET00468 | |
| 0.042 | 0.038 | 0.042 | CDK7/cyclin H inhibitor | |||
| 0.053 | 0.049 | 0.053 | Cyclin-dependent kinase 6 inhibitor | |||
| 0.192 | 0.188 | 0.206 | Antithrombotic | 0.206 0.17 DBMET00468 | DBMET00468 | |
| 0.073 | 0.069 | 0.091 | MAP kinase kinase 7 inhibitor | 0.091 0.024 DBMET00468 | DBMET00468 | |
| 0.08 | 0.076 | 0.08 | Potassium channel activator | |||
| 0.04 | 0.037 | 0.04 | 5 Hydroxytryptamine 2C agonist | |||
| 0.111 | 0.108 | 0.111 | Protein kinase (CK1) gamma 1 inhibitor | |||
| 0.039 | 0.036 | 0.039 | Histamine H2 receptor agonist | |||
| 0.006 | 0.005 | 0.006 | Integrin alpha5beta6 antagonist | |||
| 0.016 | 0.015 | 0.016 | Cyclin T1 inhibitor | |||
| 0.05 | 0.05 | 0.051 | Epithelial sodium channel blocker | 0.051 0.047 DBMET00468 | DBMET00468 | |
| 0.142 | 0.144 | 0.168 | Dyrk kinase inhibitor | 0.168 0.119 DBMET00468 | DBMET00468 | |
| 0.033 | 0.039 | 0.054 | Dopamine D5 agonist | 0.054 0.015 DBMET00468 | DBMET00468 | |
| 0.035 | 0.042 | 0.046 | NMDA receptor subunit 3B antagonist | 0.046 0.028 DBMET00468 | DBMET00468 | |
| 0.089 | 0.099 | 0.134 | DNA polymerase I inhibitor | 0.134 0.058 DBMET00468 | DBMET00468 | |
| 0.106 | 0.124 | 0.127 | Cell wall synthesis inhibitor | 0.127 0.09 DBMET00468 | DBMET00468 | |
| 0.103 | 0.121 | 0.112 | Cyclooxygenase inhibitor | 0.112 0.109 DBMET00468 | DBMET00468 | |
| 0.04 | 0.062 | 0.054 | CXC chemokine 1 receptor antagonist | 0.054 0.03 DBMET00468 | DBMET00468 | |
| 0.13 | 0.156 | 0.137 | Cyclin-dependent kinase 3 inhibitor | 0.137 0.132 DBMET00468 | DBMET00468 | |
| 0.049 | 0.077 | 0.071 | Phenylalanine 4-hydroxylase inhibitor | 0.071 0.045 DBMET00468 | DBMET00468 | |
| 0.033 | 0.063 | 0.04 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.04 0.034 DBMET00468 | DBMET00468 | |
| 0.052 | 0.082 | 0.066 | Na+ K+ transporting ATPase inhibitor | 0.066 0.064 DBMET00468 | DBMET00468 | |
| 0.078 | 0.113 | 0.09 | Carbonic anhydrase XV inhibitor | 0.09 0.082 DBMET00468 | DBMET00468 | |
| 0.044 | 0.084 | 0.059 | Purinergic P2X1 antagonist | 0.059 0.045 DBMET00468 | DBMET00468 | |
| 0.069 | 0.114 | 0.1 | UDP-glucose 4-epimerase inhibitor | 0.1 0.061 DBMET00468 | DBMET00468 | |
| 0.08 | 0.127 | 0.116 | Cyclooxygenase 1 inhibitor | 0.116 0.084 DBMET00468 | DBMET00468 | |
| 0.078 | 0.128 | 0.114 | MAP kinase kinase inhibitor | 0.114 0.08 DBMET00468 | DBMET00468 | |
| 0.069 | 0.128 | 0.106 | Cystathionine beta-synthase inhibitor | 0.106 0.07 DBMET00468 | DBMET00468 | |
| 0.042 | 0.101 | 0.064 | Histidine decarboxylase inhibitor | 0.064 0.057 DBMET00468 | DBMET00468 | |
| 0.109 | 0.172 | 0.158 | Interleukin antagonist | 0.158 0.112 DBMET00468 | DBMET00468 | |
| 0.072 | 0.159 | 0.1 | DOPA decarboxylase inhibitor | 0.1 0.075 DBMET00468 | DBMET00468 | |
| 0.168 | 0.271 | 0.241 | Antibacterial | 0.241 0.185 DBMET00468 | DBMET00468 | |
| 0.193 | 0.344 | 0.303 | Antiinflammatory | 0.303 0.213 DBMET00468 | DBMET00468 | |
| 0.056 | 0.216 | 0.078 | Estrogen-related receptor beta agonist | 0.078 0.075 DBMET00468 | DBMET00468 | |
| 0.015 | 0.207 | 0.034 | Estrogen-related receptor beta antagonist | 0.034 0.02 DBMET00468 | DBMET00468 | |
| 0.091 | 0.292 | 0.127 | MAP kinase kinase 4 inhibitor | 0.127 0.124 DBMET00468 | DBMET00468 | |
| 0.045 | 0.38 | 0.123 | Interleukin 4 antagonist | 0.123 0.081 DBMET00468 | DBMET00468 | |
| 0.029 | 0.512 | 0.116 | Farnesoid X receptor antagonist | 0.116 0.115 DBMET00468 | DBMET00468 | |
| 0.004 | 0.918 | 0.097 | Estrogen receptor beta antagonist | 0.097 0.07 DBMET00468 | DBMET00468 | |
| 0.004 | 0.955 | 0.105 | Estrogen antagonist | 0.105 0.087 DBMET00468 | DBMET00468 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |